CG Oncology SEC filings
Filter: All · 8-K · 10-Q · 10-K · Form 4
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedCG Oncology Reports Positive Phase 3 PIVOT-006 Topline Data: 68% Reduction in Recurrence Risk (HR 0.32) in Intermediate-Risk and HG Ta NMIBC; BCG-Unresponsive BLA Timing Pushed to March 2027
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedCG Oncology Q3 2026 EPS of -$0.64 Beats -$0.81 Consensus; Revenue $1.6 Million Tops $0.5 Million Estimate
Results of operations and financial condition · Other events · Financial statements and exhibits